Bone Mineral Density Screening For Older Women With Normal T-Scores May Not Needed For 15 Years
January 22, 2012 by · Leave a Comment
The U.S. Preventive Services Task Force and other organizations have recommended that women ages 65 and older be routinely screened for osteoporosis using bone mineral density (BMD) screening. However, how often women should be screened is a topic that remains controversial and undecided, with no definitive scientific evidence to provide guidance. Now a new study led by Margaret L…
New Study Points To Systemic Inflammation As An Independent Predictor of Low Bone Mineral Density (Osteopenia) In Stable COPD Patients
January 10, 2012 by · Leave a Comment
A recent study has concluded that systemic inflammation (dysregulated inflammation) is an indicator for Osteopenia (low bone mineral density) in individuals with COPD. Nutri-Med Logic Corp states that categorizing systemic inflammation, as a risk factor in Osteopenia, should not be limited to only individuals with COPD, rather to all adults.
(PRWeb January 09, 2012)
Prolia (Denosumab) Maintains Menopausal Women's Bone Density For Over Eight Years
December 14, 2011 by · Leave a Comment
Postmenopausal females with osteoporosis or low bone mass who are on Prolia (denosumab) treatment were found to have continued increase in BMD (bone mineral density) for up to eight years, Amgen announced today at the meeting of the American Society for Bone and Mineral Research, San Diego, California…
Prolia (Denosumab) Maintains Menopausal Women's Bone Density For Over Eight Years
December 7, 2011 by · Leave a Comment
Postmenopausal females with osteoporosis or low bone mass who are on Prolia (denosumab) treatment were found to have continued increase in BMD (bone mineral density) for up to eight years, Amgen announced today at the meeting of the American Society for Bone and Mineral Research, San Diego, California…
Prolia (Denosumab) Maintains Menopausal Women's Bone Density For Over Eight Years
November 24, 2011 by · Leave a Comment
Postmenopausal females with osteoporosis or low bone mass who are on Prolia (denosumab) treatment were found to have continued increase in BMD (bone mineral density) for up to eight years, Amgen announced today at the meeting of the American Society for Bone and Mineral Research, San Diego, California…
